Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bivamelagon · LB54640

Small molecule · Agonist of melanocortin-4 receptor (MC4R) · developed by Rhythm Pharmaceuticals

Phase 2 Most advanced trial (none active)
RYTM Developer
1 Registered trials

What is Bivamelagon?

Bivamelagon (LB54640) is an orally bioavailable agonist that selectively binds and activates the melanocortin-4 receptor in the brain, a receptor involved in regulating hunger, satiety and energy expenditure. It is being studied for hypothalamic obesity.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LB54640
Drug type
Small molecule
Targets
melanocortin-4 receptor (MC4R)
Mechanism
Agonist of melanocortin-4 receptor (MC4R)
Pathways
MC4R-mediated signaling pathway
Therapy area
Metabolic
Developer
Rhythm Pharmaceuticals, Inc. (RYTM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
NO1Y8WRA8N

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06046443 Phase 2 Hypothalamic Obesity Completed RYTM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypothalamic Obesity

Other drugs acting on MC4R

More from Rhythm Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the RYTM page.

Follow RYTM, the company behind Bivamelagon

See RYTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RYTM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.